| |
PRESS RELEASE
January 4, 2006
Company Press Release
SOURCE: Intarcia Therapeutics, Inc.
INTARCIA THERAPEUTICS TO PRESENT AT THE 24th ANNUAL
JPMORGAN HEALTHCARE CONFERENCE
San Francisco, Ca., – January 4, 2006 Intarcia Therapeutics,
Inc., a privately held, biopharmaceutical company, today announced
that it will present at the 24th Annual JPMorgan Healthcare
Conference at 1:00 p.m. PST on Thursday, January 12, 2006 at the
Westin St. Francis Hotel in San Francisco, California.
Alice Leung, President and Chief Executive Officer of Intarcia
Therapeutics, will provide an update on the Company’s clinical
development program for the Atamestane combination therapy in
hormone-dependent advanced breast cancer. Intarcia expects to
announce results from its first phase 3 clinical trial of Atamestane
in April 2006. The Company will also provide an update on its
development program for Omega DUROS®, a subcutaneous implant
designed to deliver omega interferon for the treatment of hepatitis
C.
About Intarcia
Intarcia Therapeutics, Inc., a privately held biopharmaceutical
company, applies a targeted approach to the acquisition, development
and commercialization of therapeutic products for use in treating
patients with cancer and infectious diseases. Intarcia’s
lead programs include a combination therapy for the treatment
of hormone-dependent breast cancer in postmenopausal women and
an implant to deliver omega interferon for the treatment of hepatitis
C.
# # #
Contact: James Ahlers
Chief Financial Officer
Intarcia Therapeutics, Inc.
510-652-2600 ext 235
| Back
|
|
